Microencapsulated IL-12 Drives Genital Tract Immune Responses to Intranasal Gonococcal Outer Membrane Vesicle Vaccine and Induces Resistance to Vaginal Infection with Diverse Strains of Neisseria gonorrhoeae.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
21 02 2023
Historique:
pubmed: 21 12 2022
medline: 25 2 2023
entrez: 20 12 2022
Statut: ppublish

Résumé

An experimental gonococcal vaccine consisting of outer membrane vesicles (OMVs) and microsphere (ms)-encapsulated interleukin-12 (IL-12 ms) induces Th1-driven immunity, with circulating and genital antibodies to Neisseria gonorrhoeae, after intravaginal (i.vag.) administration in female mice, and generates resistance to vaginal challenge infection. Because i.vag. administration is inapplicable to males and may not be acceptable to women, we determined whether intranasal (i.n.) administration would generate protective immunity against N. gonorrhoeae. Female and male mice were immunized i.n. with gonococcal OMVs plus IL-12 ms or blank microspheres (blank ms). Responses to i.n. immunization were similar to those with i.vag. immunization, with serum IgG, salivary IgA, and vaginal IgG and IgA antigonococcal antibodies induced when OMVs were administered with IL-12 ms. Male mice responded with serum IgG and salivary IgA antibodies similarly to female mice. Gamma interferon (IFN-γ) production by CD4

Identifiants

pubmed: 36537786
doi: 10.1128/msphere.00388-22
pmc: PMC9942569
doi:

Substances chimiques

Antibodies, Blocking 0
Antibodies, Bacterial 0
Interleukin-12 187348-17-0
Bacterial Vaccines 0
Interferon-gamma 82115-62-6
Immunoglobulin G 0
Immunoglobulin A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0038822

Subventions

Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R44-AI104067
Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R44-AI115877

Références

Clin Infect Dis. 2023 Feb 8;76(3):e1341-e1349
pubmed: 35642527
Mucosal Immunol. 2014 Jan;7(1):165-76
pubmed: 23757303
Infect Immun. 1999 Nov;67(11):5699-708
pubmed: 10531218
Infect Immun. 2000 Oct;68(10):5539-45
pubmed: 10992451
J Reprod Med. 1975 Jan;14(1):34-6
pubmed: 1089158
Front Immunol. 2019 Oct 15;10:2417
pubmed: 31681305
Vaccine. 1996 Jul;14(10):1001-8
pubmed: 8873395
J Exp Med. 1986 Nov 1;164(5):1735-48
pubmed: 3095479
Infect Immun. 1998 Jul;66(7):3390-6
pubmed: 9632610
PLoS One. 2012;7(7):e41260
pubmed: 22844448
Infect Immun. 1999 Jun;67(6):2884-90
pubmed: 10338495
Front Immunol. 2019 Apr 09;10:683
pubmed: 31024540
Vaccine. 2015 Feb 11;33(7):855-60
pubmed: 25562793
Mol Cell Proteomics. 2019 Jan;18(1):127-150
pubmed: 30352803
Mucosal Immunol. 2012 May;5(3):320-31
pubmed: 22354319
J Infect Dis. 2013 Dec 1;208(11):1821-9
pubmed: 24048962
mSphere. 2018 Jan 31;3(1):
pubmed: 29404418
Vaccine. 2003 May 16;21(17-18):2042-51
pubmed: 12706694
Infect Immun. 1998 Apr;66(4):1334-41
pubmed: 9529050
Lancet. 2017 Sep 30;390(10102):1603-1610
pubmed: 28705462
Mol Cell Proteomics. 2016 Jul;15(7):2338-55
pubmed: 27141096
Gene. 1999 Aug 5;236(1):179-84
pubmed: 10433979
J Antimicrob Chemother. 2016 Nov;71(11):3096-3108
pubmed: 27432602
Mediators Inflamm. 2013;2013:127017
pubmed: 24204097
Infect Immun. 1987 Aug;55(8):1755-61
pubmed: 2440807
Infect Immun. 2008 Aug;76(8):3801-7
pubmed: 18490457
Clin Infect Dis. 2019 Sep 13;69(7):1101-1111
pubmed: 30551148
Am J Reprod Immunol. 2005 May;53(5):208-14
pubmed: 15833098
J Bacteriol. 2010 Jun;192(11):2816-29
pubmed: 20363948
Mucosal Immunol. 2010 May;3(3):312-21
pubmed: 20107432
Infect Immun. 1993 Jan;61(1):314-22
pubmed: 8418053
Vaccine. 1991 Mar;9(3):154-62
pubmed: 1675029
Infect Immun. 1998 Feb;66(2):514-20
pubmed: 9453604
J Infect Dis. 1993 Sep;168(3):622-9
pubmed: 8354903
Vaccine. 1999 Aug 20;18(1-2):160-72
pubmed: 10501246
Methods Mol Med. 2003;75:687-96
pubmed: 12407772
J Proteome Res. 2013 Apr 5;12(4):1898-908
pubmed: 23410224
Infect Immun. 1996 Apr;64(4):1272-83
pubmed: 8606090
J Infect Dis. 2000 Sep;182(3):848-55
pubmed: 10950780
J Exp Med. 1988 Nov 1;168(5):1883-97
pubmed: 3141555
Mucosal Immunol. 2017 Nov;10(6):1594-1608
pubmed: 28272393
Immunol Res. 1997;16(2):187-201
pubmed: 9212364
Scand J Immunol. 1997 Nov;46(5):506-13
pubmed: 9393634
Nat Immunol. 2002 Mar;3(3):229-36
pubmed: 11850628
Emerg Infect Dis. 2016 Jun;22(6):1137-9
pubmed: 27191543
J Infect Dis. 1996 Dec;174(6):1223-37
pubmed: 8940213
Vaccine. 2020 Jun 9;38(28):4362-4373
pubmed: 32359875
Vaccine. 2010 Jul 5;28(30):4810-6
pubmed: 20483197
mBio. 2011 May 24;2(3):e00095-11
pubmed: 21610119
PLoS One. 2013 May 31;8(5):e65157
pubmed: 23741478
PLoS Pathog. 2020 Dec 8;16(12):e1008602
pubmed: 33290434
Front Immunol. 2021 Dec 17;12:781280
pubmed: 34987509
J Bacteriol. 1995 Dec;177(24):7275-9
pubmed: 8522539
Infect Immun. 2005 Jul;73(7):3945-53
pubmed: 15972481

Auteurs

Yingru Liu (Y)

Therapyx, Inc., Buffalo, New York, USA.

Laura A Hammer (LA)

Therapyx, Inc., Buffalo, New York, USA.

Jikke Daamen (J)

Intravacc, Bilthoven, The Netherlands.

Michiel Stork (M)

Intravacc, Bilthoven, The Netherlands.

Nejat K Egilmez (NK)

Therapyx, Inc., Buffalo, New York, USA.
University of Louisville, Louisville, Kentucky, USA.

Michael W Russell (MW)

Therapyx, Inc., Buffalo, New York, USA.
University at Buffalo, Buffalo, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH